Cibus (CBUS) 10-Q 1 May 23 2023 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2023	Apr. 28, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Trading Symbol	CLXT
Entity Registrant Name	Calyxt, Inc.
Entity Central Index Key	0001705843
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		4,973,687
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	001-38161
Entity Tax Identification Number	27-1967997
Entity Address, Address Line One	2800 Mount Ridge Road
Entity Address, City or Town	Roseville
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55113-1127
City Area Code	651
Local Phone Number	683-2807
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock ($0.0001 par value)
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Transition Report	false
Document Quarterly Report	true

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 2,054	$ 3,427
Restricted cash	0	99
Prepaid expenses and other current assets	529	606
Total current assets	2,583	4,132
Land, buildings, and equipment	4,104	4,516
Operating lease right-of-use assets	13,493	13,615
Other non-current assets	105	158
Total assets	20,285	22,421
Current liabilities:
Accounts payable	327	340
Accrued expenses	1,052	173
Accrued compensation	180	107
Due to related parties	63	175
Current portion of financing lease obligations	0	97
Common stock warrants	1,110	291
Short-term debt	1,000	0
Other current liabilities	483	479
Total current liabilities	4,215	1,662
Operating lease obligations	13,342	13,447
Other non-current liabilities	61	79
Total liabilities	17,618	15,188
Stockholders' equity:
Common stock, $0.0001 par value; 275,000,000 shares authorized; 4,983,081 shares issued and 4,973,066 shares outstanding as of March 31, 2023, and 4,894,477 shares issued and 4,884,462 shares outstanding as of December 31, 2022	5	5
Additional paid-in capital	221,250	220,422
Common stock in treasury, at cost; 10,015 shares as of March 31, 2023, and December 31, 2022	(1,043)	(1,043)
Accumulated deficit	(217,545)	(212,151)
Total stockholders' equity	2,667	7,233
Total liabilities and stockholders' equity	$ 20,285	$ 22,421

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	275,000,000	275,000,000
Common stock, shares issued	4,983,104	4,894,497
Common stock, shares outstanding	4,973,088	4,884,481
Treasury stock, shares	10,016	10,016

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenue	$ 42	$ 32
Costs of goods sold	0	0
Gross profit	42	32
Operating expenses:
Research and development	2,209	2,941
Selling, general, and administrative	2,296	3,180
Total operating expenses	4,505	6,121
Loss from operations	(4,463)	(6,089)
Interest, net	(21)	(17)
Non-operating income (expenses)	(910)	487
Loss before income taxes	(5,394)	(5,619)
Income taxes	0	0
Net loss	$ (5,394)	$ (5,619)
Earnings Per Share, Basic	$ (1.09)	$ (1.34)
Earnings Per Share, Diluted	$ (1.09)	$ (1.34)
Weighted Average Number of Shares Outstanding, Basic	4,940,693	4,202,011
Weighted Average Number of Shares Outstanding, Diluted	4,940,693	4,202,011
Anti-dilutive stock options, restricted stock units, performance stock units, and common stock warrants	1,826,029	1,627,637

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	ATM Facility Member	IPO [Member]	Common Stock [Member]	Common Stock [Member] IPO [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member] ATM Facility Member	Additional Paid-In Capital [Member] IPO [Member]	Shares in Treasury [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2021	$ 14,132			$ 4		$ 211,263			$ (1,043)	$ (196,092)
Beginning balance, shares at Dec. 31, 2021				3,877,400
Net loss	(5,619)									(5,619)
Stock-based compensation	531					531
Issuance of common stock from stock-based compensation awards,shares				8,779
Issuance of common stock		$ (7)	$ 5,052		$ 1		$ (7)	$ 5,051
Issuance of common stock, shares					388,000
Cumulative effect of adoption of lease accounting standard	832									832
Ending balance, shares at Mar. 31, 2022				4,274,179
Ending balance at Mar. 31, 2022	14,921			$ 5		216,838			(1,043)	(200,879)
Beginning balance at Dec. 31, 2022	7,233			$ 5		220,422			(1,043)	(212,151)
Beginning balance, shares at Dec. 31, 2022				4,884,481
Net loss	(5,394)									(5,394)
Stock-based compensation	828					828
Issuance of common stock from stock-based compensation awards,shares				88,607
Ending balance, shares at Mar. 31, 2023				4,973,088
Ending balance at Mar. 31, 2023	$ 2,667			$ 5		$ 221,250			$ (1,043)	$ (217,545)

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parenthetical) $ in Millions	3 Months Ended
	Mar. 31, 2022 USD ($)
Follow-on Public Offering [Member]
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 0.5

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating activities
Net loss	$ (5,394)	$ (5,619)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation and amortization	486	370
Stock-based compensation	828	531
Unrealized (gain) loss on mark-to-market of common stock warrants	819	(435)
Changes in operating assets and liabilities:
Due to/from related parties	(112)	(108)
Prepaid expenses and other current assets	56	(110)
Accounts payable	(13)	(145)
Accrued expenses	879	37
Accrued compensation	73	(313)
Other	3	(612)
Net cash used by operating activities	(2,375)	(6,404)
Investing activities
Purchases of land, buildings, and equipment	0	(545)
Net cash (used) provided by investing activities	0	(545)
Financing activities
Proceeds from the issuance of common stock and pre-funded warrants	0	11,209
Costs incurred related to the issuance of common stock and pre-funded warrants	0	(704)
Proceeds from interim funding provided by Cibus Global, LLC	1,000	0
Repayments of financing lease obligations	(97)	(94)
Net cash provided by financing activities	903	10,411
Net (decrease) increase in cash, cash equivalents, and restricted cash	(1,472)	3,462
Cash, cash equivalents, and restricted cash - beginning of period	3,526	14,421
Cash, cash equivalents, and restricted cash - end of period	$ 2,054	$ 17,883

Basis Of Presentation & Summary

Basis Of Presentation & Summary Of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis Of Presentation & Summary Of Significant Accounting Policies	1. BASIS OF PRESENTATION & SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The unaudited consolidated financial statements of Calyxt, Inc. (Calyxt or the Company) have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP or GAAP) for interim financial information and with the rules and regulations of the Securities and Exchange Commission (SEC) applicable to interim financial statements. In the Company’s opinion, the accompanying consolidated financial statements reflect all adjustments necessary for a fair presentation of its statements of financial position, results of operations, and cash flows for the periods presented but they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Except as otherwise disclosed herein, these adjustments consist of normal recurring items. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole or any other interim period. The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the consolidated financial statements and during the reporting period. Actual results could materially differ from these estimates. Certain prior year amounts have been reclassified to conform to the current year presentation. For further information, refer to the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K/A 10-Q 10-K/A Net Loss Per Share Due to the Company’s net loss position for the three months ended March 31, 2023, and March 31, 2022, all of its outstanding stock options, restricted stock units (RSUs), performance stock units (PSUs), and warrants to purchase common stock (Common Warrants) are considered anti-dilutive and excluded from the calculation of net loss per share. Accordingly, the treasury method was not used in determining the number of anti-dilutive stock options, RSUs, PSUs, or Common Warrants. Warrants The Company issued pre-funded (Pre-Funded follow-on Follow-On Pre-Funded , Pre-Funded Pre-Funded The Company also issued Common Warrants in the Follow-On Common Warrants are reported at fair value with changes in fair value reported in earnings. The Company reports the changes in fair value of the Common Warrants in non-operating Recently Issued Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) No. 2016-02, Leases No. 2018-10, 2018-11, Leases (Topic right-of-use The Company adopted the New Lease Standard as of January 1, 2022, using the transition method which does not require revisions to comparative periods. The Company elected to implement the transition package of practical expedients permitted within the New Lease Standard, which among other things, allows it to carry forward the historical lease classification. In addition, the Company elected the hindsight practical expedient to determine the lease term for existing leases and it also made an accounting policy election to not record leases with an initial term of 12 months or less on its consolidated balance sheet. The Company’s adoption of the New Lease Standard required it to remove the previously reported amounts for land, buildings, and equipment associated with its headquarters and laboratory facility lease as well as the associated liability. The Company assessed the elements of its lease agreement and upon adoption, recorded an operating lease associated with the sale leaseback of the land component of the lease, and a second operating lease associated with the building component of the lease. The Company recorded operating lease assets and liabilities of Reverse Stock Split In an effort to regain compliance with the listing rule of the Nasdaq Capital market requiring that the bid price of the Company’s common stock be $ 1.00 the All share and per share amounts in the consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this Reverse Stock S t fractional shares were issued in connection with the Reverse Stock Split and instead, fractional shares were rounded up to the nearest whole share number.

Going Concern

Going Concern	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	2. GOING CONCERN The Company has incurred losses since its inception. The Company’s net loss was $5.4 million for the three months ended March 31, 2023, and it used $2.4 million of cash for operating activities for the three months ended March 31, 2023. The Company’s primary sources of liquidity are its cash and cash equivalents and funding from Cibus pursuant to the Interim Funding (as defined below), with additional liquidity accessible, subject to market conditions and other factors, including limitations that may apply to the Company under applicable SEC and Nasdaq Capital Market (Nasdaq) regulations, from the capital markets, including under the Open Market Sale Agreement SM As of March 31, 2023, the Company had $2.1 million of cash and cash equivalents. As of March 31, 2023, current liabilities were $4.2 million. Pursuant to the Agreement and Plan of Merger (the Merger Agreement) among the Company, Cibus and certain other parties thereto, the Company and Cibus agreed that beginning at the earlier of March 15, 2023, and the date Calyxt’s unrestricted cash balance first drops below $ 1.5 3.0 4.0 0.5 1.0 Subsequent to March 31, 2023, and prior to the filing date of this Form 10-Q, the Company received another $0.5 million of Interim Funding from Cibus. On October 3, 2022, the Company entered into an amendment to the Open Market Sale Agreement with Jefferies for the ATM Facility that enables it, subject to the applicable baby shelf rules described below, to offer and sell up to 1,566,100 shares of its common stock. At its discretion, the Company determines the timing and number of shares to be issued under the ATM Facility. From January 1, 2023, through the date of this report, the Company has not issued any shares under the ATM Facility. During the February 2022 Offering, the Company issued 388,000 shares of its common stock, Pre-Funded Follow-On The Company has incurred losses since its inception and anticipates that it will continue to generate losses for the next several years. Over the longer term and until the Company can generate cash flows sufficient to support its operating capital requirements, it expects to finance a portion of future cash needs through (i) cash on hand, (ii) commercialization activities, which may result in various types of revenue streams from (a) future product development agreements and technology licenses, including upfront and milestone payments, annual license fees, and royalties; and (b) product sales from its proprietary BioFactory production system; (iii) government or other third-party funding, (iv) public or private equity or debt financings, (v) the execution of strategic transactions, or (vi) a combination of the foregoing. However, capital generated by commercialization activities, if any, is expected to be received over a period of time and near-term additional capital may not be available on reasonable terms, if at all. Although the Company has access to the ATM Facility, based on the Company’s public float as of the date of the filing of its Annual Report on Form 10-K/A, S-3, one-third The Company’s ability to continue as a going concern will depend on its ability to obtain additional public or private equity or debt financing, obtain government or private grants and other similar types of funding, to consummate the Transactions or an alternative strategic transaction, attain further operating efficiencies, reduce or contain expenditures, and, ultimately, to generate revenue. The Company believes that its cash and cash equivalents as of March 31, 2023, considering continuing actions taken to reduce its operating expenses to enable the Transactions to close, the legal settlement discussed in Note 8 to the consolidated financial statements, and the Interim Funding are sufficient to fund its operations through the second quarter of 2023. The Company’s management has concluded there is substantial doubt regarding its ability to continue as a going concern because it will need to raise additional capital to support its business plan for a period of 12 months or more from the date of this filing. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. Management has implemented various cost reductions and other cash-focused measures to manage liquidity. If the Company is unable to raise additional capital in a sufficient amount or on acceptable terms or to consummate the Transactions or an alternative strategic transaction, the Company may have to implement increasingly stringent cost saving measures and significantly delay, scale back, or cease operations, in part or in full. If the Company raises additional funds through the issuance of additional debt or equity securities, including as part of a strategic alternative, it could result in substantial dilution to its existing stockholders and increased fixed payment obligations, and these securities may have rights senior to those of the Company’s shares of common stock. Any of these events could significantly harm the Company’s business, financial condition, and prospects.

Financial Instruments Measured

Financial Instruments Measured at Fair Value and Concentrations of Credit Risk	3 Months Ended
	Mar. 31, 2023
Text Block [Abstract]
Financial Instruments Measured at Fair Value and Concentrations of Credit Risk	3. FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE AND CONCENTRATIONS OF CREDIT RISK Financial Instruments Measured at Fair Value and Financial Statement Presentation Financial instruments including cash and cash equivalents, restricted cash, accounts payable, short-term debt, and all other current liabilities have carrying values that approximate fair value. The Company measures Common Warrants on a quarterly basis. The accounting guidance establishes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as of the measurement date as follows: Level 1: Fair values are based on unadjusted quoted prices in active trading markets for identical assets and liabilities. Level 2: Fair values are based on observable quoted prices other than those in Level 1, such as quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets. Level 3: Fair values are based on at least one significant unobservable input for the asset or liability. Fair Value Measurements and Financial Statement Presentation The fair values of the Company’s financial instruments measured at fair value and their respective levels in the fair value hierarchy as of March 31, 2023, and December 31, 2022, were as follows: March 31, 2023 March 31, 2023 Fair Values of Assets Fair Values of Liabilities In Thousands Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Other items reported at fair value: Common stock warrants $ — $ — $ — $ — $ — $ — $ 1,110 $ 1,110 Total $ — $ — $ — $ — $ — $ — $ 1,110 $ 1,110 December 31, 2022 December 31, 2022 Fair Values of Assets Fair Values of Liabilities In Thousands Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Other items reported at fair value: Common stock warrants $ — $ — $ — $ — $ — $ — $ 291 $ 291 Total $ — $ — $ — $ — $ — $ — $ 291 $ 291 The Company estimates the fair value of the Common Warrants as of the date of issuance and at the end of every fiscal period using a Black-Scholes option pricing model, which requires it to make predictive assumptions regarding future stock price volatility and dividend yield. The Company estimates the risk-free interest rate based on the United States Treasury zero-coupon The estimated fair values of the Common Warrants, and the assumptions used for the Black-Scholes option pricing model were as follows: As of As of 2023 2022 Estimated fair value of Common Warrants $ 1.43 $ 0.37 Assumptions: Risk-free interest rate 3.8 % 4.0 % Expected volatility 90.0 % 85.0 % Expected term to liquidation (in years) 4.4 4.6 As of March 31, 2023, the Company had no other financial instruments measured at fair value. Concentrations of Credit Risk The Company invests its cash, cash equivalents, and restricted cash in highly liquid securities and investment funds. The Company diversifies the risk associated with investing in securities by allocating its investments to a diverse portfolio of short-dated, high investment-grade securities, which it classifies as short-term investments that are recorded at fair value in its consolidated financial statements. The Company maintains the credit risk in this portfolio in accordance with its internal policies and if necessary, makes changes to investments to minimize credit risk. The Company has not experienced any counterparty credit losses. As of March 31, 2023, and December 31, 2022, the Company did not hold any short-term investments.

Related-Party Transactions

Related-Party Transactions	3 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
Related-Party Transactions	4. RELATED-PARTY TRANSACTIONS The Company is party to several agreements that govern its relationship with Cellectis, some of which require the Company to make payments to Cellectis. Pursuant to the Company’s management services agreement with Cellectis, it incurred no management fee expenses for the three months ended March 31, 2023, and 2022. Cellectis has also guaranteed the lease agreement for the Company’s headquarters. Cellectis’ guarantee of the Company’s obligations under the lease will terminate at the end of the second consecutive calendar year in which the Company’s tangible net worth exceeds $300 million. The Company agreed to indemnify Cellectis for any obligations incurred by Cellectis under its guaranty of the obligations under the lease, effective upon Cellectis’ ownership falling to 50 percent or less of the Company’s outstanding common stock. This indemnification obligation was triggered in October 2022. TALEN ® ® ®

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2023
Federal Home Loan Banks [Abstract]
Stockholders' Equity	5. STOCKHOLDERS’ EQUITY Follow-On On February 23, 2022, the Company completed the Follow-On Pre-Funded Pre-Funded Pre-Funded Each Pre-Funded Pre-Funded paid-in Pre-Funded , Common Stock Warrants Each Common Warrant entitles the holder to purchase one share of common stock at an exercise price of $14.10 per share. The Common Warrants became exercisable on August 23, 2022 , Warrant transactions for the three months ended March 31, 2023, are as follows: Number of Weighted-Average Outstanding as of December 31, 2022: 776,000 $ 14.10 Issued — — Forfeited/canceled — — Exercised — Outstanding as of March 31, 2023: 776,000 $ 14.10 Exercisable as of March 31, 2023: 776,000 $ 14.10 ATM Facility On September 21, 2021, the Company entered into an ATM Facility with Jefferies LLC, as sole selling agent. The Company issued approximately 140,000 shares of common stock under the ATM Facility in 2021. In the aggregate, the Company received net proceeds from the ATM Facility of $4.1 million through early January 2022. On October 3, 2022, the Company entered into an amendment to the Open Market Sale Agreement that enables it, subject to the applicable baby shelf rules, to offer and sell up to 1,566,100 shares of its common stock. At its discretion, the Company determines the timing and number of shares to be issued under the ATM Facility. From January 1, 2023, through the date of this report, the Company has not issued any additional shares under the ATM Facility.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2023
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	6. STOCK-BASED COMPENSATION The Company uses broad-based stock plans to attract and retain highly qualified officers and employees and to help ensure that management’s interests are aligned with those of its shareholders. The Company has also granted equity-based awards to directors, non-employees, and certain employees of Cellectis. In December 2014, the Company adopted the Calyxt, Inc. Equity Incentive Plan (2014 Plan), which allowed for the grant of stock options, and in June 2017, it adopted the 2017 Omnibus Plan (2017 Plan), which allowed for the grant of stock options, RSUs, PSUs and other types of equity awards. In July 2021, the Company also adopted the Calyxt, Inc. Employee Inducement Incentive Plan (the Inducement Plan), from which PSUs were granted to Michael A. Carr. As of March 31, 2023, 9,259 shares were registered and available for grant under effective registration statements, while 238,983 shares were available for grant in the form of stock options, restricted stock, RSUs, and PSUs under the 2017 Plan. Stock-based awards currently outstanding also include awards granted under the 2014 Plan and the Inducement Plan. No further awards will be granted under either the 2014 Plan or the Inducement Plan Stock Options The estimated fair values of stock options granted, and the assumptions used for the Black-Scholes option pricing model were as follows: Three Months Ended March 31, 2023 2022 Estimated fair values of stock options granted $ — $ 9.71 Assumptions: Risk-free interest rate — 1.9% - 2.4 % Expected volatility — 89.7% - 91.8 % Expected term (in years) — 5.75 - 6.89 The Company estimates the fair value of each stock option on the grant date, or other measurement date if applicable, using a Black-Scholes option pricing model, which requires it to make predictive assumptions regarding employee exercise behavior, future stock price volatility, and dividend yield. The Company estimates the risk-free interest rate based on the United States Treasury zero-coupon Option strike prices are set at 100 percent or more of the closing share price on the date of grant and generally vest over three Modification of Stock Options On March 1, 2023, the Company’s Board of Directors (Board) approved the modification of the award terms of all outstanding stock options with a 90-day Information on stock option activity is as follows: Options Weighted- Options Weighted- Balance as of December 31, 2022 339,707 $ 99.35 584,171 $ 73.51 Granted — — Exercised — — Forfeited or expired (21,206 ) 38.12 Balance as of March 31, 2023 381,873 $ 92.18 562,965 $ 74.85 Stock-based compensation expense related to stock option awards is as follows: Three Months Ended March 31, In Thousands 2023 2022 Stock-based compensation expense $ 354 $ 180 As of March 31, 2023, options outstanding and exercisable had no aggregate intrinsic value and the weighted average remaining contractual term was 5.2 years as of that date. Net cash proceeds from the exercise of stock options less shares used for minimum withholding taxes and the intrinsic value of options exercised were as follows: Three Months Ended March 31, In Thousands 2023 2022 Net cash proceeds $ — $ — Intrinsic value of options exercised $ — $ — As of March 31, 2023, unrecognized compensation expense related to non-vested Restricted Stock Units The Company grants RSUs which generally vest over three Number of Weighted- Unvested balance as of December 31, 2022 122,914 $ 19.90 Granted 348,759 4.34 Vested (68,831 ) 15.33 Forfeited (9,442 ) 17.24 Unvested balance as of March 31, 2023 393,400 $ 6.97 The total grant-date fair value of restricted stock unit awards that vested is as follows: Three Months Ended March 31, In Thousands 2023 2022 Grant-date fair value $ 1,055 $ 617 Stock-based compensation expense related to RSUs is as follows: Three Months Ended March 31, In Thousands 2023 2022 Stock-based compensation expense $ 311 $ 205 As of March 31, 2023, unrecognized compensation expense related to RSUs was $2.2 million. This expense will be recognized over 29 months on average. The Company accounts for stock-based compensation awards granted to employees of Cellectis as deemed dividends. The Company recorded deemed dividends as follows: Three Months Ended March 31, In Thousands 2023 2022 Deemed dividends from grants to Cellectis employees $ — $ 37 Performance Stock Units From time-to-time, 2022 Grant In March 2022, the Company granted 53,000 PSUs under the 2017 Plan to five employees including four executive officers. The PSUs include three annual performance periods (2022, 2023, and 2024) and target performance levels for each of those periods linked to the achievement of Company objectives as determined annually for the respective period by the Compensation Committee. Once the annual objectives are approved, the associated expense will be recognized on a straight-line basis over the period through the determination date, which can be no later than March 15 of the following year. Earned awards will be settled in shares of Company stock no later than the March 15 determination date in the following calendar year. The grant date for the tranche of awards linked to 2022 performance was May 4, 2022, and on March 1, 2023, the Company’s Board determined the 2022 tranche of PSUs would vest at 100%. Determination of expense for the 2023 and 2024 tranches of PSUs for the four executive officers will be made when the associated business objectives are determined. 2021 Grant In July 2021, the Company granted 60,000 PSUs under the Inducement Plan to Mr. Carr. The PSUs will vest if the Company’s stock remains above three specified price levels for thirty calendar days over the three-year performance period. The PSUs will be settled in unrestricted shares of the Company’s common stock on the vesting date. 2019 Grant In June 2022, PSUs granted to two executive officers in 2019 were forfeited because the underlying performance criteria were not met. These PSUs contained a market condition and had a five-year service period. The Company continue s PSU activity for the three months ended March 31, 2022, is as follows: Number of Unvested balance as of December 31, 2022 113,000 Granted — Vested (17,670 ) Forfeited (1,666 ) Unvested balance as of March 31, 2023 93,664 Stock-based compensation expense related to PSUs is as follows: Three Months Ended In Thousands 2023 2022 Stock-based compensation expense $ 163 $ 146 As of March 31, 2023, unrecognized compensation expense related to PSUs was $0.8 million. This expense will be recognized over 16 months on average.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	7. INCOME TAXES The Company provides a valuation allowance when it is more likely than not that it will not realize a portion of the deferred tax assets. The Company has established a full valuation allowance for deferred tax assets due to the uncertainty that enough taxable income will be generated in the taxing jurisdiction to utilize the assets. Therefore, the Company has not reflected any benefit of such deferred tax assets in the accompanying consolidated financial statements. As of March 31, 2023, there were no material changes to what the Company disclosed regarding tax uncertainties or penalties as of December 31, 2022.

Leases, Commitments, and Contin

Leases, Commitments, and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Leases, Commitments, and Contingencies	8. LEASES, COMMITMENTS, AND CONTINGENCIES Litigation and Claims In the fourth quarter of 2022, the Company reached a settlement with one of its technology vendors regarding alleged intellectual property infringement. As a result of the settlement, the Company received $0.75 million in the fourth quarter of 2022, and it received the final installment of $0.75 million in the first quarter of 2023. The Company is not currently a party to any other material pending legal proceedings. Leases The Company had an equipment financing arrangement that was considered a financing-type lease. This equipment financing arrangement was repaid in full in the first quarter of 2023. The Company was required to deposit cash into a restricted account in an amount equal to the future rent payments required by the lease. As of March 31, 2023, the remaining restricted cash had been returned to the Company. The Company is obligated under a non-cancellable The Roseville, Minnesota lease includes four options to extend the lease for five years. These options to extend the lease are not recognized as part of the ROU assets and operating lease liabilities as it is not reasonably certain that the Company will exercise those options. The Company’s agreement does not include options to terminate the lease. The components of lease expense were as follows: Three Months Ended March 31, In Thousands 2023 2022 Finance lease costs $ 3 $ 9 Operating lease costs 388 399 Variable lease costs 233 231 Total $ 624 $ 639 Operating lease cost for short-term leases was not material for the three months ended March 31, 2023, or March 31, 2022. Supplemental cash flow information related to leases was as follows: Three Months Ended March 31, In Thousands 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows (operating leases) $ 72 $ 67 Financing cash flows (finance leases) 97 94 Supplemental balance sheet information related to leases was as follows: As of March 31, 2023 As of December 31, 2022 Operating Financing Operating Financing Weighted average remaining lease term (years) 15.1 — 15.3 0.4 Weighted average discount rate 7.9 % — 7.9 % 8.1 % As of March 31, 2023, future minimum payments under leases were as follows: In Thousands Operating Financing Total Remainder of 2023 $ 1,102 $ — $ 1,102 2024 1,480 — 1,480 2025 1,479 — 1,479 2026 1,479 — 1,479 2027 1,479 — 1,479 2028 1,553 — 1,553 Thereafter 15,438 — 15,438 24,010 — 24,010 Less: imputed interest (10,268 ) — (10,268 ) Total $ 13,742 $ — $ 13,742

Supplemental Information

Supplemental Information	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplemental Information	9. SUPPLEMENTAL INFORMATION Certain balance sheet amounts are as follows: In Thousands As of As of Cash, cash equivalents, and restricted cash: Cash and cash equivalents $ 2,054 $ 3,427 Restricted cash — 99 Total $ 2,054 $ 3,526 In Thousands As of As of Prepaid expenses and other current assets: Common warrants – financing costs $ 375 $ 396 Prepaid expenses and other current assets 154 210 Total $ 529 $ 606 In Thousands As of As of Other current liabilities: Operating lease obligations – current $ 400 $ 367 Other current liabilities 83 112 Total $ 483 $ 479 Certain statements of operations amounts are as follows: Three Months Ended March 31, In Thousands 2023 2022 Stock-based compensation expense: Research and development $ 184 $ 30 Selling, general, and administrative 644 501 Total $ 828 $ 531 Three Months Ended March 31, In Thousands 2023 2022 Interest, net: Interest expense $ (3 ) $ (10 ) Interest income 3 1 Common stock warrants - financing costs amortization (21 ) (8 ) Total $ (21 ) $ (17 ) Supplemental statement of cash flows information is as follows: As of March 31, In Thousands 2023 2022 Interest paid $ 3 $ 8 Non-cash As of March 31, In Thousands 2023 2022 Receivable from Jefferies for shares issued under ATM facility $ — $ (260 ) Non-cash $ — $ (202 ) Unpaid stock offering costs included in stockholders’ equity $ — $ 257 Cumulative effect of adoption of lease accounting standard on stockholders’ equity $ — $ 832 Establishment of operating lease right-of-use $ — $ 14,090

Interim Funding

Interim Funding	3 Months Ended
	Mar. 31, 2023
Disclosure Of Interim Funding [Abstract]
Interim Funding	10. INTERIM FUNDING Pursuant to the Merger Agreement, beginning at the earlier of March 15, 2023, and the date Calyxt’s unrestricted cash balance first drops below $1.5 million, Calyxt could request, and Cibus agreed to provide, an unsecured, interest-free revolving line of credit of up to $3.0 million in cash, which amount may be increased to $4.0 million if Cibus elects to extend the outside date (as defined in the Merger Agreement) to June 30, 2023. Funds can be drawn by Calyxt in $0.5 million increments and may only be used to fund operating expenses incurred in the ordinary course of business consistent with past practice and consistent with the negative covenants in the Merger Agreement. The full outstanding balance of the Interim Funding will be reduced to zero in connection with the closing of the Transactions, if consummated. The full outstanding balance of the Interim Funding will be forgiven by Cibus if the Merger Agreement is terminated for any reason other than under certain conditions, as detailed in the Merger Agreement. The Interim Funding is subject to acceleration in connection with certain bankruptcy events. As of March 31, 2023, the Company had received $1.0 million of Interim Funding from Cibus. Subsequent to March 31, 2023, and prior to the filing date of this Form 10-Q, the Company received another $0.5 million of Interim Funding from Cibus.

Basis Of Presentation & Summa_2

Basis Of Presentation & Summary Of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Net Loss Per Share	Net Loss Per Share Due to the Company’s net loss position for the three months ended March 31, 2023, and March 31, 2022, all of its outstanding stock options, restricted stock units (RSUs), performance stock units (PSUs), and warrants to purchase common stock (Common Warrants) are considered anti-dilutive and excluded from the calculation of net loss per share. Accordingly, the treasury method was not used in determining the number of anti-dilutive stock options, RSUs, PSUs, or Common Warrants.
Warrants	Warrants The Company issued pre-funded (Pre-Funded follow-on Follow-On Pre-Funded , Pre-Funded Pre-Funded The Company also issued Common Warrants in the Follow-On Common Warrants are reported at fair value with changes in fair value reported in earnings. The Company reports the changes in fair value of the Common Warrants in non-operating
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) No. 2016-02, Leases No. 2018-10, 2018-11, Leases (Topic right-of-use The Company adopted the New Lease Standard as of January 1, 2022, using the transition method which does not require revisions to comparative periods. The Company elected to implement the transition package of practical expedients permitted within the New Lease Standard, which among other things, allows it to carry forward the historical lease classification. In addition, the Company elected the hindsight practical expedient to determine the lease term for existing leases and it also made an accounting policy election to not record leases with an initial term of 12 months or less on its consolidated balance sheet. The Company’s adoption of the New Lease Standard required it to remove the previously reported amounts for land, buildings, and equipment associated with its headquarters and laboratory facility lease as well as the associated liability. The Company assessed the elements of its lease agreement and upon adoption, recorded an operating lease associated with the sale leaseback of the land component of the lease, and a second operating lease associated with the building component of the lease. The Company recorded operating lease assets and liabilities of
Reverse Stock Split	Reverse Stock Split In an effort to regain compliance with the listing rule of the Nasdaq Capital market requiring that the bid price of the Company’s common stock be $ 1.00 the All share and per share amounts in the consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this Reverse Stock S t fractional shares were issued in connection with the Reverse Stock Split and instead, fractional shares were rounded up to the nearest whole share number.

Financial Instruments Measure_2

Financial Instruments Measured at Fair Value and Concentrations of Credit Risk (Tables)	3 Months Ended
	Mar. 31, 2023
Text Block [Abstract]
Summary of Fair Value Measurements and Financial Statement Presentation	The fair values of the Company’s financial instruments measured at fair value and their respective levels in the fair value hierarchy as of March 31, 2023, and December 31, 2022, were as follows: March 31, 2023 March 31, 2023 Fair Values of Assets Fair Values of Liabilities In Thousands Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Other items reported at fair value: Common stock warrants $ — $ — $ — $ — $ — $ — $ 1,110 $ 1,110 Total $ — $ — $ — $ — $ — $ — $ 1,110 $ 1,110 December 31, 2022 December 31, 2022 Fair Values of Assets Fair Values of Liabilities In Thousands Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Other items reported at fair value: Common stock warrants $ — $ — $ — $ — $ — $ — $ 291 $ 291 Total $ — $ — $ — $ — $ — $ — $ 291 $ 291
Summary of Fair Value of the Common Warrants	The estimated fair values of the Common Warrants, and the assumptions used for the Black-Scholes option pricing model were as follows: As of As of 2023 2022 Estimated fair value of Common Warrants $ 1.43 $ 0.37 Assumptions: Risk-free interest rate 3.8 % 4.0 % Expected volatility 90.0 % 85.0 % Expected term to liquidation (in years) 4.4 4.6

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2023
Text Block [Abstract]
Disclosure of Warrants Transactions	Number of Weighted-Average Outstanding as of December 31, 2022: 776,000 $ 14.10 Issued — — Forfeited/canceled — — Exercised — Outstanding as of March 31, 2023: 776,000 $ 14.10 Exercisable as of March 31, 2023: 776,000 $ 14.10

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Fair Values of Stock Options Granted and Assumptions used in Black-Scholes Model	The estimated fair values of stock options granted, and the assumptions used for the Black-Scholes option pricing model were as follows: Three Months Ended March 31, 2023 2022 Estimated fair values of stock options granted $ — $ 9.71 Assumptions: Risk-free interest rate — 1.9% - 2.4 % Expected volatility — 89.7% - 91.8 % Expected term (in years) — 5.75 - 6.89
Summary of Stock Option Activity	Information on stock option activity is as follows: Options Weighted- Options Weighted- Balance as of December 31, 2022 339,707 $ 99.35 584,171 $ 73.51 Granted — — Exercised — — Forfeited or expired (21,206 ) 38.12 Balance as of March 31, 2023 381,873 $ 92.18 562,965 $ 74.85
Schedule of Net Cash Proceeds from Exercise of Stock Options Less Shares Used for Minimum Withholding Taxes and Intrinsic Value of Options Exercised	Net cash proceeds from the exercise of stock options less shares used for minimum withholding taxes and the intrinsic value of options exercised were as follows: Three Months Ended March 31, In Thousands 2023 2022 Net cash proceeds $ — $ — Intrinsic value of options exercised $ — $ —
Summary of Activity of Restricted Stock Units	Information on restricted stock unit activity is as follows: Number of Weighted- Unvested balance as of December 31, 2022 122,914 $ 19.90 Granted 348,759 4.34 Vested (68,831 ) 15.33 Forfeited (9,442 ) 17.24 Unvested balance as of March 31, 2023 393,400 $ 6.97
Summary of Grant Date Fair Value of Restricted Stock Unit Awards Vested	The total grant-date fair value of restricted stock unit awards that vested is as follows: Three Months Ended March 31, In Thousands 2023 2022 Grant-date fair value $ 1,055 $ 617
Summary of Stock-Based Compensation Granted As Deemed Dividends	The Company accounts for stock-based compensation awards granted to employees of Cellectis as deemed dividends. The Company recorded deemed dividends as follows: Three Months Ended March 31, In Thousands 2023 2022 Deemed dividends from grants to Cellectis employees $ — $ 37
Share-Based Payment Arrangement, Performance Shares, Outstanding Activity	PSU activity for the three months ended March 31, 2022, is as follows: Number of Unvested balance as of December 31, 2022 113,000 Granted — Vested (17,670 ) Forfeited (1,666 ) Unvested balance as of March 31, 2023 93,664
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Stock-based Compensation Expense	Stock-based compensation expense related to stock option awards is as follows: Three Months Ended March 31, In Thousands 2023 2022 Stock-based compensation expense $ 354 $ 180
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Stock-based Compensation Expense	Stock-based compensation expense related to RSUs is as follows: Three Months Ended March 31, In Thousands 2023 2022 Stock-based compensation expense $ 311 $ 205
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Stock-based Compensation Expense	Stock-based compensation expense related to PSUs is as follows: Three Months Ended In Thousands 2023 2022 Stock-based compensation expense $ 163 $ 146

Leases, Commitments, and Cont_2

Leases, Commitments, and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2023
Lease, Cost [Abstract]
Summary of Future Minimum Rental Payments	As of March 31, 2023, future minimum payments under leases were as follows: In Thousands Operating Financing Total Remainder of 2023 $ 1,102 $ — $ 1,102 2024 1,480 — 1,480 2025 1,479 — 1,479 2026 1,479 — 1,479 2027 1,479 — 1,479 2028 1,553 — 1,553 Thereafter 15,438 — 15,438 24,010 — 24,010 Less: imputed interest (10,268 ) — (10,268 ) Total $ 13,742 $ — $ 13,742
Summary of Other Information Related to Leases	Supplemental cash flow information related to leases was as follows: Three Months Ended March 31, In Thousands 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows (operating leases) $ 72 $ 67 Financing cash flows (finance leases) 97 94 Supplemental balance sheet information related to leases was as follows: As of March 31, 2023 As of December 31, 2022 Operating Financing Operating Financing Weighted average remaining lease term (years) 15.1 — 15.3 0.4 Weighted average discount rate 7.9 % — 7.9 % 8.1 %
Summary of Lease Cost	The components of lease expense were as follows: Three Months Ended March 31, In Thousands 2023 2022 Finance lease costs $ 3 $ 9 Operating lease costs 388 399 Variable lease costs 233 231 Total $ 624 $ 639

Supplemental Information (Table

Supplemental Information (Tables)	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Certain Balance Sheet Amounts	Certain balance sheet amounts are as follows: In Thousands As of As of Cash, cash equivalents, and restricted cash: Cash and cash equivalents $ 2,054 $ 3,427 Restricted cash — 99 Total $ 2,054 $ 3,526 In Thousands As of As of Prepaid expenses and other current assets: Common warrants – financing costs $ 375 $ 396 Prepaid expenses and other current assets 154 210 Total $ 529 $ 606 In Thousands As of As of Other current liabilities: Operating lease obligations – current $ 400 $ 367 Other current liabilities 83 112 Total $ 483 $ 479
Schedule of Certain Statements of Operations Amounts	Certain statements of operations amounts are as follows: Three Months Ended March 31, In Thousands 2023 2022 Stock-based compensation expense: Research and development $ 184 $ 30 Selling, general, and administrative 644 501 Total $ 828 $ 531 Three Months Ended March 31, In Thousands 2023 2022 Interest, net: Interest expense $ (3 ) $ (10 ) Interest income 3 1 Common stock warrants - financing costs amortization (21 ) (8 ) Total $ (21 ) $ (17 )
Schedule of Statements of Certain Statements of Cash Flows Amounts	Supplemental statement of cash flows information is as follows: As of March 31, In Thousands 2023 2022 Interest paid $ 3 $ 8 Non-cash As of March 31, In Thousands 2023 2022 Receivable from Jefferies for shares issued under ATM facility $ — $ (260 ) Non-cash $ — $ (202 ) Unpaid stock offering costs included in stockholders’ equity $ — $ 257 Cumulative effect of adoption of lease accounting standard on stockholders’ equity $ — $ 832 Establishment of operating lease right-of-use $ — $ 14,090

Basis Of Presentation & Summa_3

Basis Of Presentation & Summary Of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended
	Apr. 24, 2023	Mar. 31, 2023	Mar. 31, 2023	Dec. 31, 2022	Feb. 23, 2022	Jan. 01, 2022
Property, Plant and Equipment [Line Items]
Operating lease right-of-use assets		$ 13,493	$ 13,493	$ 13,615
Operating lease obligations		$ 13,342	13,342	$ 13,447
Common Stock Warrants [Member]
Property, Plant and Equipment [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 14.1
Pre Funded Warrants [Member]
Property, Plant and Equipment [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.0001
Common Stock [Member]
Property, Plant and Equipment [Line Items]
Description Of Bid Price		1.00 per share or higher
Subsequent Event [Member]
Property, Plant and Equipment [Line Items]
Stockholders' Equity, Reverse Stock Split	the Company effected a one-for-ten reverse stock split (the Reverse Stock Split) of its common stock.
Subsequent Event [Member] | Fractional Shares [Member]
Property, Plant and Equipment [Line Items]
Stock Issued During Period, Shares, Reverse Stock Splits	0
Accounting Standards Update 2016-02 [Member]
Property, Plant and Equipment [Line Items]
Operating lease right-of-use assets						$ 14,100
Operating lease obligations						$ 14,100
Stockholders equity cumulative effect of adoption of lease accounting standard.			$ 800

Going Concern - Additional Info

Going Concern - Additional Information (Detail) - USD ($)				1 Months Ended	3 Months Ended
	Mar. 31, 2023	Mar. 15, 2023	Feb. 28, 2022	Apr. 30, 2023	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Oct. 03, 2022	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net loss					$ (5,394,000)	$ (5,619,000)
Net cash used by operating activities					(2,375,000)	(6,404,000)
Cash, cash equivalents, and restricted cash	$ 2,054,000				2,054,000	17,883,000	$ 3,526,000		$ 14,421,000
Current liabilities	4,215,000				4,215,000		$ 1,662,000
Common stock, issued and sold			388,000
Issuance of common stock			$ 10,000,000
After deduction of underwriting discounts and estimated other offering expenses			$ 900,000
Proceeds From Interim Funding					1,000,000	$ 0
Cibus Global, LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds From Interim Funding	1,000,000
Unrestricted cash		$ 1,500,000
Revolving Credit Facility [Member] | Cibus Global, LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from Lines of Credit		500,000
Line of credit facility, increase (decrease), net		4,000,000
Line of credit facility, maximum borrowing capacity		$ 3,000,000
ATM Facility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock shares subscribed but not issued								1,566,100
Shelf Registration Statement [Member] | ATM Facility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Minimum public float	$ 75,000,000				$ 75,000,000
Maximum [Member] | ATM Facility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock shares subscribed but not issued								1,566,100
Pre-funded Warrants [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants issued (in shares)			388,000
Common Warrants [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants issued (in shares)			776,000
Subsequent Event [Member] | Cibus Global, LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from Lines of Credit				$ 500,000
Subsequent Event [Member] | Revolving Credit Facility [Member] | Cibus Global, LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from Lines of Credit				$ 500,000

Financial Instruments Measure_3

Financial Instruments Measured at Fair Value and Concentrations of Credit Risk - Summary of Fair Value Measurements and Financial Statement Presentation (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Liabilities	$ 1,110	$ 291
Common Stock Warrants [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Liabilities	1,110	291
Level 3 [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Liabilities	1,110	291
Level 3 [Member] | Common Stock Warrants [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Liabilities	$ 1,110	$ 291

Financial instruments and finan

Financial instruments and financial risk management - Summary of Fair Value of the Common Warrants (Detail)	Mar. 31, 2023 yr	Dec. 31, 2022 yr
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated fair value of Common Warrants	1.43	0.37
Expected term to liquidation (in years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumptions	4.4	4.6
Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumptions	90	85
Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumptions	3.8	4

Financial Instruments Measure_4

Financial Instruments Measured at Fair Value and Concentrations of Credit Risk - Additional Information (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Short-term investments	$ 0
Unrealized commodity derivative losses from hedging contracts sold	0
Corporate Debt Securities [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Other financial instruments	$ 0

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Detail) - Cellectis [Member] $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
Related Party Transaction [Line Items]
Minimum net worth required	$ 300
Maximum [Member]
Related Party Transaction [Line Items]
Threshold percentage of ownership in outstanding common stock to enact indemnification agreement	50%

Stockholders' Equity - Summary

Stockholders' Equity - Summary Of Warrants Transactions (Detail) - Common Stock Warrant Units [Member]	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Disclosure of Warrants Transactions [Line Items]
Number of restricted stock units outstanding, Unvested beginning balance | shares	776,000
Weighted-average grant date fair value, Unvested beginning balance | $ / shares	$ 14.1
Number of restricted stock units outstanding, Issued | shares	0
Weighted-average grant date fair value, Issued | $ / shares	$ 0
Number of restricted stock units outstanding, Unvested ending balance | shares	776,000
Weighted-average grant date fair value, Unvested ending balance | $ / shares	$ 14.1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares	776,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 14.1

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Feb. 28, 2022	Feb. 23, 2022	Sep. 21, 2021	Oct. 03, 2022
Equity, Class of Treasury Stock [Line Items]
Common stock, issued and sold	388,000
Net proceeds from issuance of common stock and exercise of overallotment	$ 10
After deduction of underwriting discounts and estimated other offering expenses	$ 0.9
ATM Facility [Member]
Equity, Class of Treasury Stock [Line Items]
Common stock shares subscribed but not issued				1,566,100
ATM Facility [Member] | Maximum [Member]
Equity, Class of Treasury Stock [Line Items]
Common stock shares subscribed but not issued				1,566,100
Pre Funded Warrants [Member]
Equity, Class of Treasury Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights		$ 0.0001
Pre Funded Warrants [Member] | Maximum [Member]
Equity, Class of Treasury Stock [Line Items]
Warrants issued (in shares)	388,000
Common Warrants [Member] | Maximum [Member]
Equity, Class of Treasury Stock [Line Items]
Warrants issued (in shares)	776,000
Date from which Warrants or Rights Exercisable		Aug. 23, 2027
Common Warrants [Member] | Minimum [Member]
Equity, Class of Treasury Stock [Line Items]
Date from which Warrants or Rights Exercisable		Aug. 23, 2022
Common Stock Warrants [Member]
Equity, Class of Treasury Stock [Line Items]
Common Stock, Voting Rights		4.99
Class of warrant or right, exercise price of warrants or rights		$ 14.1
Common Stock Warrants [Member] | ATM Facility [Member]
Equity, Class of Treasury Stock [Line Items]
Common stock, issued and sold			140,000
Net proceeds from issuance of common stock and exercise of overallotment			$ 4.1
Follow-on Public Offering [Member]
Equity, Class of Treasury Stock [Line Items]
Common stock, issued and sold		388,000
Common stock issued price per share		$ 14.1
Net proceeds from issuance of common stock and exercise of overallotment		$ 10
After deduction of underwriting discounts and estimated other offering expenses		$ 0.9
Follow-on Public Offering [Member] | Pre Funded Warrants [Member]
Equity, Class of Treasury Stock [Line Items]
Common stock issued price per share		$ 14.099
Follow-on Public Offering [Member] | Pre Funded Warrants [Member] | Maximum [Member]
Equity, Class of Treasury Stock [Line Items]
Warrants issued (in shares)		388,000
Follow-on Public Offering [Member] | Common Warrants [Member] | Maximum [Member]
Equity, Class of Treasury Stock [Line Items]
Warrants issued (in shares)		776,000

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($) shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares registered and available for grant | shares	9,259
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage | $	$ 0.2
Phantom Share Units (PSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	100%
Employee Stock Option Vested [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage | $	$ 0.1
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common shares available for issue | shares	238,983

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Fair Values of Stock Options Granted and Assumptions used in Black-Scholes Model (Detail) - Stock Options [Member] - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated fair values of stock options granted	$ 0	$ 9.71
Risk-free interest rate	0%
Expected volatility	0%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate		1.90%
Expected volatility		89.70%
Expected term (in years)		5 years 9 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate		2.40%
Expected volatility		91.80%
Expected term (in years)		6 years 10 months 20 days

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Options - Additional Information (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options priced at fair market value, Percent	100%
Stock option expiration period	10 years
2017 Omnibus Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option, vesting period	3 years
2017 Omnibus Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option, vesting period	6 years
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average remaining contractual term	5 years 2 months 12 days
Aggregate intrinsic value of options outstanding and exercisable	$ 0
Unrecognized stock-based compensation expense related to non-vested stock options	$ 2,500
Unrecognized stock-based compensation expense, expected recognition weighted-average period	20 months

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Stock Option Activity (Detail)	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Share-based Payment Arrangement [Abstract]
Options Exercisable, Beginning Balance | shares	339,707
Options Exercisable, Ending Balance | shares	381,873
Weighted-Average Exercise Price Per Share, Beginning Balance | $ / shares	$ 99.35
Weighted-Average Exercise Price Per Share, Ending Balance | $ / shares	$ 92.18
Options Outstanding, Beginning Balance | shares	584,171
Options Outstanding, Granted | shares	0
Options Outstanding, Exercised | shares	0
Options Outstanding, Forfeited or expired | shares	(21,206)
Options Outstanding, Ending Balance | shares	562,965
Weighted-Average Exercise Price Per Share, Beginning Balance | $ / shares	$ 73.51
Weighted-Average Exercise Price Per Share, Granted | $ / shares	0
Weighted-Average Exercise Price Per Share, Exercised | $ / shares	0
Weighted-Average Exercise Price Per Share, Forfeited or expired | $ / shares	38.12
Weighted-Average Exercise Price Per Share, Ending Balance | $ / shares	$ 74.85

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Stock-Based Compensation Expense Related to Stock Option Awards (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 828	$ 531
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 354	$ 180

Stock-Based Compensation - Su_4

Stock-Based Compensation - Summary of Net Cash Proceeds from Exercise of Stock Options Less Shares Used for Minimum Withholding Taxes and Intrinsic Value of Options Exercised (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Net cash proceeds	$ 0	$ 0
Intrinsic value of options exercised	$ 0	$ 0

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Units - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
2017 Omnibus Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
2017 Omnibus Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	6 years
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to restricted stock units	$ 2.2
Unrecognized stock-based compensation expense, expected recognition weighted-average period	29 months
Restricted Stock Units [Member] | 2017 Omnibus Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Restricted Stock Units [Member] | 2017 Omnibus Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years

Stock-Based Compensation - Su_5

Stock-Based Compensation - Summary of Activity of Restricted Stock Units (Detail) - Restricted Stock Units [Member]	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted stock units outstanding, Unvested beginning balance | shares	122,914
Number of restricted stock units outstanding, Granted | shares	348,759
Number of restricted stock units outstanding, Vested | shares	(68,831)
Number of restricted stock units outstanding, Cancelled | shares	(9,442)
Number of restricted stock units outstanding, Unvested ending balance | shares	393,400
Weighted-average grant date fair value, Unvested beginning balance | $ / shares	$ 19.9
Weighted-average grant date fair value, Granted | $ / shares	4.34
Weighted-average grant date fair value, Vested | $ / shares	15.33
Weighted-average grant date fair value, Cancelled | $ / shares	17.24
Weighted-average grant date fair value, Unvested ending balance | $ / shares	$ 6.97

Stock-Based Compensation - Su_6

Stock-Based Compensation - Summary of Grant Date Fair Value of Restricted Stock Unit Awards Vested (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant-date fair value	$ 1,055	$ 617

Stock-Based Compensation - Su_7

Stock-Based Compensation - Summary of Stock-Based Compensation Expenses Related to Restricted Stock Units (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 828	$ 531
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 311	$ 205

Stock-Based Compensation - Su_8

Stock-Based Compensation - Summary of Stock-Based Compensation Granted as Deemed Dividends (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Nonemployee Restricted Stock Units [Member] | Cellectis [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deemed dividends from grants to Cellectis employee	$ 0	$ 37

Stock-Based Compensation - Perf

Stock-Based Compensation - Performance Stock Units - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($) Day shares	Jul. 31, 2021 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted	9,259
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to performance stock units | $	$ 0.8
Unrecognized stock-based compensation expense, expected recognition weighted-average period	16 months
Performance Stock Units [Member] | 2021 Grant | Inducement Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Consecutive trading day | Day	30
Performance Stock Units [Member] | 2021 Grant | Mr Carr [Member] | Inducement Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted		60,000
Performance Stock Units [Member] | 2022 Grant | Mr Carr [Member] | 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted	53,000

Stock-Based Compensation- Summa

Stock-Based Compensation- Summary Of Share Based Compensation Performance Shares Award Outstanding Activity (Detail)	3 Months Ended
	Mar. 31, 2023 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning	113,000
Vested	(17,670)
Forfeited	(1,666)
Ending	93,664

Stock-Based Compensation - Su_9

Stock-Based Compensation - Summary of Stock-Based Compensation Expenses Related to Performance Stock Units (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 828	$ 531
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 163	$ 146

Leases, Commitments, and Cont_3

Leases, Commitments, and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Other Commitments [Line Items]
Operating Lease, Right-of-Use Asset	$ 13,493	$ 13,615
Litigation Settlement, Amount Awarded from Other Party	750	$ 750
Roseville, MN Lease [Member]
Other Commitments [Line Items]
Operating Lease, Right-of-Use Asset	$ 13,500
Lessee, Operating Lease, Remaining Lease Term	15 years 1 month 6 days
Maximum [Member] | Roseville, MN Lease [Member]
Other Commitments [Line Items]
Lessee, Operating Lease, Remaining Lease Term	5 years

Leases, Commitments, and Cont_4

Leases, Commitments, and Contingencies - Summary of Lease Cost (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Lease, Cost [Abstract]
Finance lease cost	$ 3	$ 9
Operating lease, cost	388	399
Variable lease, cost	233	231
Total	$ 624	$ 639

Leases, Commitments, and Cont_5

Leases, Commitments, and Contingencies - Summary of Other Information Related to Leases (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Cash Paid for Amounts Included in the Measurement of Lease Liabilities [Abstract]
Operating cash flows (operating leases)	$ 72	$ 67
Financing cash flows (finance leases)	$ 97	$ 94
Operating Lease, Weighted average remaining lease term (years)	15 years 1 month 6 days		15 years 3 months 18 days
Finance Lease, Weighted average remaining lease term (years)			4 months 24 days
Operating Lease, Weighted average discount rate	7.90%		7.90%
Finance Lease, Weighted average discount rate	0%		8.10%

Leases, Commitments, and Cont_6

Leases, Commitments, and Contingencies - Summary of Future Minimum Rental Payments (Detail) $ in Thousands	Mar. 31, 2023 USD ($)
Schedule Of Future Minimum Rental Payments [Abstract]
Operating, Remainder of 2023	$ 1,102
Operating, 2024	1,480
Operating, 2025	1,479
Operating, 2026	1,479
Operating, 2027	1,479
Operating, 2028	1,553
Operating, Thereafter	15,438
Total including interest, Operating	24,010
Operating, Less: imputed interest	(10,268)
Total	13,742
Finance Lease, Liability, to be Paid, Remainder of Fiscal Year	0
Financing, 2024	0
Financing, 2025	0
Financing, 2026	0
Financing, 2027	0
Financing, 2028	0
Financing, Thereafter	0
Total including interest, Financing	0
Financing, Less: imputed interest	0
Total	0
Remainder of 2023	1,102
2024	1,480
2025	1,479
2026	1,479
2027	1,479
2028	1,553
Thereafter	15,438
Total including interest, Financing	24,010
Less: imputed interest	(10,268)
Total	$ 13,742

Supplemental Information - Summ

Supplemental Information - Summary of Certain Balance Sheet Amounts (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Condensed Balance Sheet Statements Captions [Line Items]
Cash and cash equivalents	$ 2,054	$ 3,427
Restricted cash	0	99
Total	2,054	3,526
Common Warrants Financing Cost	375	396
Prepaid expenses and other current assets	154	210
Total	529	606
Operating lease obligations – current	400	367
Other current liabilities	83	112
Total	$ 483	$ 479

Supplemental Information - Su_2

Supplemental Information - Summary of Certain Statements of Operations Amounts (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Condensed Income Statements, Captions [Line Items]
Stock-based compensation expenses	$ 828	$ 531
Interest expense	(3)	(10)
Interest income	3	1
Common stock warrants - financing costs amortization	(21)	(8)
Total	(21)	(17)
Research and Development [Member]
Condensed Income Statements, Captions [Line Items]
Stock-based compensation expenses	184	30
Selling, General, and Administrative [Member]
Condensed Income Statements, Captions [Line Items]
Stock-based compensation expenses	$ 644	$ 501

Supplemental Information - Su_3

Supplemental Information - Summary of Statements of Certain Statements of Cash Flows Amounts (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Condensed Financial Information Disclosure [Abstract]
Receivable from Jefferies for shares issued under ATM Facility	$ 0	$ (260)
Non-cash additions to land, buildings, and equipment	0	(202)
Unpaid stock offering costs included in stockholders' equity	0	257
Cumulative effect of adoption of lease accounting standard on stockholders' equity	0	832
Establishment of right-to-use assets and associated operating lease liabilities	0	14,090
Interest paid	$ 3	$ 8

Interim Funding - Additional In

Interim Funding - Additional Information (Detail) - USD ($) $ in Thousands			1 Months Ended	3 Months Ended
	Mar. 31, 2023	Mar. 15, 2023	Apr. 30, 2023	Mar. 31, 2023	Mar. 31, 2022
Disclosure Of Interim Funding [Line Items]
Proceeds From Interim Funding				$ 1,000	$ 0
Cibus Global, LLC [Member]
Disclosure Of Interim Funding [Line Items]
Unrestricted cash		$ 1,500
Proceeds From Interim Funding	$ 1,000
Revolving Credit Facility [Member] | Cibus Global, LLC [Member]
Disclosure Of Interim Funding [Line Items]
Proceeds from Lines of Credit		500
Line of credit facility, increase (decrease), net		4,000
Line of credit facility, maximum borrowing capacity		$ 3,000
Subsequent Event [Member] | Cibus Global, LLC [Member]
Disclosure Of Interim Funding [Line Items]
Proceeds from Lines of Credit			$ 500
Subsequent Event [Member] | Revolving Credit Facility [Member] | Cibus Global, LLC [Member]
Disclosure Of Interim Funding [Line Items]
Proceeds from Lines of Credit			$ 500